Literature DB >> 6214990

Biliary concentrations of piperacillin in patients undergoing cholecystectomy.

J A Giron, B R Meyers, S Z Hirschman.   

Abstract

Piperacillin is a new semisynthetic, expanded-spectrum penicillin with marked activity against Pseudomonas aeruginosa. The biliary excretion of piperacillin was studied in patients undergoing cholecystectomy. Concentrations of piperacillin in common duct bile at 35 to 90 min postinfusion of 1-g doses ranged from 31 to 920 micrograms/ml, with a mean (+/- standard deviation) of 467 +/- 363 micrograms/ml. Gallbladder piperacillin levels at 30 to 75 min postinfusion ranged from 2.2 to 80 micrograms/ml, with a mean of 27 +/- 31 micrograms/ml. No correlation occurred with peak serum level of antibiotic, creatinine, bilirubin, or alkaline phosphatase. Significant amounts of piperacillin were excreted via the biliary system.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6214990      PMCID: PMC181416          DOI: 10.1128/AAC.19.2.309

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  Piperacillin and carbenicillin; a collaborative in vitro comparison against 10,838 clinical bacterial isolates.

Authors:  R N Jones; P C Fuchs; E H Gerlach; T L Gavan
Journal:  Cleve Clin Q       Date:  1979

2.  Biliary excretion of antibiotics in man.

Authors:  G Acocella; R Mattiussi; F B Nicolis; R Pallanza; L T Tenconi
Journal:  Gut       Date:  1968-10       Impact factor: 23.059

3.  Pharmacokinetics of intravenous piperacillin in patients undergoing chronic hemodialysis.

Authors:  E L Francke; G B Appel; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1979-12       Impact factor: 5.191

4.  Biliary excretion of antibiotics.

Authors:  L J Schoenfield
Journal:  N Engl J Med       Date:  1971-05-27       Impact factor: 91.245

5.  Pharmacokinetics of piperacillin following intravenous administration.

Authors:  M A Evans; P Wilson; T Leung; J D Williams
Journal:  J Antimicrob Chemother       Date:  1978-05       Impact factor: 5.790

6.  Susceptibility of gram-negative aerobic bacilli resistant to carbenicillin in a general hospital to piperacillin and ticarcillin.

Authors:  J E McGowan; P M Terry
Journal:  Antimicrob Agents Chemother       Date:  1979-01       Impact factor: 5.191

7.  In vitro activity of piperacillin, a new semisynthetic penicillin with an unusually broad spectrum of activity.

Authors:  L Verbist
Journal:  Antimicrob Agents Chemother       Date:  1978-03       Impact factor: 5.191

8.  Comparative study of piperacillin, ticarcillin, and carbenicillin pharmacokinetics.

Authors:  B R Meyers; S Z Hirschman; L Strougo; E Srulevitch
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

  8 in total
  9 in total

Review 1.  Antibiotics in the treatment of biliary infection.

Authors:  J S Dooley; J M Hamilton-Miller; W Brumfitt; S Sherlock
Journal:  Gut       Date:  1984-09       Impact factor: 23.059

Review 2.  Antibiotic pharmacokinetics in cystic fibrosis. Differences and clinical significance.

Authors:  R de Groot; A L Smith
Journal:  Clin Pharmacokinet       Date:  1987-10       Impact factor: 6.447

3.  Pharmacokinetics and clinical study of cefotetan in bile: prophylactic use in biliary tract surgery.

Authors:  P Cherrier; P Perrin; S Gueye; A M Bosio; P Tinel; P Blot; R Richer; F Fauvelle
Journal:  Pharm World Sci       Date:  1993-04-23

4.  Biliary excretion of aztreonam in patients with biliary tract disease.

Authors:  O V Martinez; J U Levi; R G Devlin
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

5.  Single-dose pharmacokinetics of piperacillin and tazobactam in infants and children.

Authors:  M D Reed; J Goldfarb; T S Yamashita; E Lemon; J L Blumer
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

6.  Plasma levels of piperacillin and vancomycin used as prophylaxis in liver transplant patients.

Authors:  M Dupon; G Janvier; G Vinçon; S Winnock; F Demotes-Mainard; O Capeyron; J Saric
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

7.  Experimental studies of biliary excretion of piperacillin.

Authors:  P Calhoun; K B Brown; R Strunk; D A Krusch; W M Scheld; J B Hanks
Journal:  Ann Surg       Date:  1987-04       Impact factor: 12.969

8.  The effect of piperacillin dose on elimination kinetics in renal impairment.

Authors:  G R Aronoff; R S Sloan; M E Brier; F C Luft
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

9.  Pharmacokinetics of piperacillin in subjects with various degrees of renal function.

Authors:  P G Welling; W A Craig; R W Bundtzen; F W Kwok; A U Gerber; P O Madsen
Journal:  Antimicrob Agents Chemother       Date:  1983-06       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.